(FDA approved in bold)

• Diabetic gastroparesis
  
• Nausea and vomiting (postoperative, chemotherapy)
  
• Small bowel intubation
  
• Symptomatic gastroesophageal reflux
  
• Migraine
  
• Tics in Gilles de la Tourette syndrome (GTS)

• Dopamine receptor antagonism (specifically D2) decreases nausea. It may also increase absorption of coadministered drugs. May stimulate GI motility by sensitizing tissues to the actions of acetylcholine or from 5-HT₄ receptor agonism

• 30–60 minutes with oral dose for nausea. Gastroparesis improves maximally by 3 weeks

• Use at lowest effective dose
  
• Continue to assess effect of the medication and if it is still needed

• Increase dose, or discontinue and change to another agent
  
• Migraine: change to another antiemetic (prochlorperazine, droperidol, chlorpromazine) or combine with other agents
  
• Gastroparesis: domperidone (where available) is an alternative. Smaller, more frequent meals with low fat and fiber might improve symptoms

• Migraine: often combined with NSAIDs and triptans or ergots. Usually not used as monotherapy
  
• Gastroparesis: may be combined with erythromycin, Botulinum toxin, electrical gastric stimulation

• None required